Nefopam Holsten (Nefopam Hydrochloride)

Nefopam works by inhibiting the reuptake of serotonin, norepinephrine and dopamine, and by blocking voltage‑dependent sodium and calcium channels in the central nervous system. This combination reduces neuronal excitability and modulates pain transmission, providing analgesia without engaging opioid receptors.

The specific dose of Nefopam Holsten is determined by the prescribing clinician based on the patient’s condition, age, weight and overall health. Dosage regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Safety data for Nefopam during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Nefopam Holsten, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with opioid analgesics, Nefopam provides pain relief without the risk of dependence or respiratory depression. Relative to NSAIDs, it lacks anti‑inflammatory activity and does not cause gastrointestinal ulceration, but it may have a higher incidence of central nervous system side effects such as dizziness or seizures.

Nefopam Holsten should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Nefopam Holsten is administered orally. The tablet or capsule should be swallowed whole with a glass of water, unless the prescribing information advises otherwise. It is not intended for parenteral or topical use.

The most serious adverse reactions include seizures, tachycardia and significant hypotension. Patients experiencing these symptoms should seek immediate medical attention, and clinicians should monitor cardiovascular and neurological status, especially in individuals with pre‑existing conditions.

Nefopam Holsten is contraindicated in patients currently taking monoamine oxidase inhibitors, those with a known seizure disorder, and individuals with uncontrolled severe cardiovascular disease. It should also be avoided in patients with known hypersensitivity to nefopam or any of its excipients.